© 1991 by Oxford University Press
Journal of the National Cancer Institute, Vol. 83, No. 13, 920-926,
July 3, 1991
© 1991 Oxford University Press
High-Dose Chemotherapy With Reinfusion of Purged Autologous Bone Marrow Following Dose-Intense Induction as Initial Therapy for Metastatic Breast Cancer
1The Johns Hopkins Oncology Center Baltimore, Md.
2Fairfax Hospital Fairfax, Va.
*Correspondence to: M. John Kennedy, MB MRCPI, Oncology 137, The Johns Hopkins Oncology Center, 600 N. Wolfe St, Baltimore, MD 21205.
We assessed the toxicity and efficacy of high-dose chemotherapy consolidation with reinfusion of purged autologous bone marrow in women with metastatic breast cancer responding to a dose-intense outpatient regimen. Thirty women with hormone-unresponsive metastatic breast cancer, previously untreated with adjuvant doxorubicin or with any chemotherapy for metastatic disease, were treated with cyclophosphamide, methotrexate, doxorubicin, fluorouracil, vincristine, and leucovorin for 16 weeks. Twenty-four patients responded to therapy; 8 showed a complete response, and 16 showed a partial response. These patients proceeded to the next phase of the protocol, ie, marrow harvest and treatment with 6000 mg/m2 cyclophosphamide and 800 mg/m2 thiotepa given over 4 days. Harvested marrow was purged with 100 µg/mL 4-hydroperoxycyclophosphamide, and all patients engrafted satisfactorily. The predominant side effects were myelosuppressive and gastrointestinal, and there were no deaths from toxic effects. Three of the 16 patients who showed a partial response after the outpatient phase of treatment achieved a complete response after high-dose therapy. The partial response seen in two more patients converted to a complete response at all sites except bone. The median time to disease progression for all patients in this study was 13 months, and the median survival was 22 months. Four of the original 30 patients remained without disease progression a median of 27 months from entry into the study. This study indicates that this dose-intense regimen can be safely administered, even with the use of purged marrow, with an acceptable toxicity profile. This approach results in a high response rate in women with metastatic breast cancer and could form the basis for a regimen to be tested in the high-risk adjuvant setting. [J Natl Cancer Inst 83: 920–926, 1991]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Kroger, M. Frick, O. Gluz, S. Mohrmann, B. Metzner, C. Jackisch, Y. Ko, H.-W. Lindemann, C. R. Meier, H. P. Lohrmann, et al. Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer J. Clin. Oncol., August 20, 2006; 24(24): 3919 - 3926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mayer Listen to all the voices: an advocate's perspective on early access to investigational therapies Clinical Trials, April 1, 2006; 3(2): 149 - 153. [Abstract] [PDF]
|
|
|
|
 |
|
 M. S. Tallman, R. Gray, N. J. Robert, C. F. LeMaistre, C. K. Osborne, W. P. Vaughan, W. J. Gradishar, T. M. Pisansky, J. Fetting, E. Paietta, et al. Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer N. Engl. J. Med., July 3, 2003; 349(1): 17 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nottage and L. L. Siu Principles of Clinical Trial Design J. Clin. Oncol., September 15, 2002; 20(90001): 42s - 46. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Dolan, K. Freund, and J. Walsh Update in Women's Health Ann Intern Med, March 19, 2002; 136(6): 453 - 462. [Full Text] [PDF]
|
|
|
|
|
|
G. C. de Gast, F. A. Vyth-Dreese, W. Nooijen, C. J.C. van den Bogaard, J. Sein, M. M.J. Holtkamp, G. A.M. Linthorst, J. W. Baars, J. H. Schornagel, and S. Rodenhuis Reinfusion of Autologous Lymphocytes With Granulocyte-Macrophage Colony-Stimulating Factor Induces Rapid Recovery of CD4+ and CD8+ T Cells After High-Dose Chemotherapy for Metastatic Breast Cancer J. Clin. Oncol., January 1, 2002; 20(1): 58 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Patnaik, J. MacKinnon, P. Goss, T. Nagy, K. Stewart, A. Keating, and M. Crump Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2363 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al. Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer JAMA, October 13, 1999; 282(14): 1335 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]
|
|
|
|
|
|
D. Adkins, R. Brown, K. Trinkaus, R. Maziarz, S. Luedke, C. Freytes, B. Needles, D. Wienski, P. Fracasso, T. Pluard, et al. Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 2006 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kouroussis, N. Androulakis, S. Kakolyris, J. Souglakos, T. Kotsakis, D. Mavroudis, K. Katsogridakis, N. Vardakis, D. Hatzidaki, G. Samonis, et al. Dose-Escalation Study of Docetaxel in Combination With Mitoxantrone as First-Line Treatment in Patients With Metastatic Breast Cancer J. Clin. Oncol., March 1, 1999; 17(3): 862 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Subramanyan and M. J. Kennedy Breast Cancer: High-Dose Therapy Oncologist, October 1, 1998; 3(5): 289 - 299. [Abstract] [Full Text]
|
|
|
|
|
|
T. Makatsoris and M. V. Seiden High-Dose Therapy for Ovarian Carcinoma Oncologist, October 1, 1997; 2(5): 330 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hess, E. C. Bright, C. Thoburn, G. B. Vogelsang, R. J. Jones, and M. J. Kennedy Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide Blood, March 15, 1997; 89(6): 2203 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Somlo, I. Sniecinski, T. Odom-Maryon, B. Nowicki, W. Chow, V. Hamasaki, L. Leong, K. Margolin, R. Morgan Jr, J. Raschko, et al. Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer Blood, March 1, 1997; 89(5): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Pavletic and J. O. Armitage Bone Marrow Transplantation for Cancer--An Update Oncologist, June 1, 1996; 1(3): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Hillner, T. J. Smith, and C. E. Desch Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results JAMA, April 15, 1992; 267(15): 2055 - 2061. [Abstract] [PDF]
|
|